Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals Reports Q3 2026 Revenues of $1.2B and Raises Full-Year Guidance

Mixed Impact 4 of 5 earnings

Jazz Pharmaceuticals announced its third quarter 2026 financial results, highlighting record quarterly revenues of $1.2 billion and raising its full-year 2026 total revenue guidance to a range of $4.775 billion to $4.85 billion. The company reported a GAAP net loss of $483.4 million for the quarter, primarily driven by a $754 million acquired in-process research and development expense related to the Actio Biosciences acquisition. Shareholders saw solid commercial execution, including growth in key product sales like Xywav and the recent launch of Ziihera.

Key points

  • Total revenues reached $1.24 billion in 3Q26, representing a 10% increase year-over-year.
  • GAAP net loss was $483.4 million in 3Q26, impacted by a $754 million acquired IPR&D charge for the Actio acquisition.
  • Full-year 2026 total revenue guidance was raised to $4.775 billion to $4.85 billion.
  • Xywav net product sales grew 12% year-over-year to $483 million in 3Q26.

The filing

CompanyJazz Pharmaceuticals (JAZZ)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:07 PM ET
Accession number0001232524-26-000056

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 3, 2026, 8:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.